Macimorelin, marketed as Macrilen, is an orally administered ghrelin receptor agonist and the one agent in the secretagogue family that holds FDA approval. Its indication is diagnostic rather than therapeutic: it is used to evaluate suspected adult growth hormone deficiency.
This guide situates Macimorelin within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.
Why growth hormone deficiency requires provocative testing
Growth hormone is secreted in pulses, with levels falling to near-undetectable between them. A random growth hormone measurement is therefore uninterpretable — a low value may reflect a trough in a perfectly normal pattern rather than deficiency. This is one of the most common misunderstandings in this area, and it is the reason direct-to-consumer growth hormone panels are close to meaningless.
Diagnosis instead requires a provocative stimulation test: administer a stimulus, then measure whether the pituitary responds appropriately. The reference standard has long been the insulin tolerance test, which deliberately induces hypoglycemia to provoke growth hormone release. It works, and it is unpleasant and carries real risk, being contraindicated in patients with seizure disorders or cardiovascular disease.
How macimorelin works as a test
Macimorelin activates the growth hormone secretagogue receptor, providing a strong stimulus to pituitary growth hormone release. Because it is taken orally as a solution, no infusion or induced hypoglycemia is required.
The procedure involves administering the weight-based dose after fasting, then drawing serial growth hormone levels over a defined interval. A peak below the established cut-off supports a diagnosis of growth hormone deficiency; an adequate rise argues against it.
Its approval rested on demonstrating acceptable agreement with insulin tolerance testing while being substantially better tolerated and simpler to administer. That combination is what has made it a practical alternative.
Interpretation and cautions
Macimorelin carries a labeled concern regarding QT interval prolongation, so concomitant medications that prolong QT are a relevant consideration before testing.
Interpretation requires context. Test performance varies with body mass index — obesity blunts stimulated growth hormone responses across every provocative test, which can produce results suggesting deficiency in patients who do not have it. Certain medications and untreated deficiencies in other pituitary hormones also affect results.
This is properly specialist territory. The diagnosis of adult growth hormone deficiency, and any decision about replacement, belongs with endocrinology rather than being made from a screening panel.
Why this belongs in a peptide formulary
Macimorelin is worth knowing precisely because of the contrast it draws. It is the same receptor target as MK-677, GHRP-2 and the rest of the secretagogue family — and it is the only one that completed a regulatory pathway, for a narrowly defined diagnostic purpose.
That contrast is useful with patients. Activating this receptor is legitimate, well-characterized pharmacology; what has actually been demonstrated and approved is a single diagnostic application, not a therapeutic one.
Learn peptides the right way
Empire Medical Training's Peptide Therapy Master Course is a CME-accredited program covering growth hormone axis biology and diagnostic testing, patient selection, monitoring, regulatory status, and compliant sourcing — taught by board-certified physicians. Available in person and via livestream. It is also Course 1 of Empire’s Peptide Therapy Certification, which adds business, marketing and healthcare-law training, a documented case series and a final exam.
Explore the Certification →